KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Long-Term Deferred Tax: 2021-2023

Historic Long-Term Deferred Tax for Moderna (MRNA) over the last 3 years, with Dec 2023 value amounting to $81.0 million.

  • Moderna's Long-Term Deferred Tax was N/A to $81.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $81.0 million, marking a year-over-year change of. This contributed to the annual value of $81.0 million for FY2023, which is 91.75% down from last year.
  • Latest data reveals that Moderna reported Long-Term Deferred Tax of $81.0 million as of FY2023, which was down 91.75% from $982.0 million recorded in FY2022.
  • In the past 5 years, Moderna's Long-Term Deferred Tax registered a high of $982.0 million during FY2022, and its lowest value of $81.0 million during FY2023.
  • Its 3-year average for Long-Term Deferred Tax is $463.0 million, with a median of $326.0 million in 2021.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first spiked by 201.23% in 2022, then slumped by 91.75% in 2023.
  • Yearly analysis of 3 years shows Moderna's Long-Term Deferred Tax stood at $326.0 million in 2021, then spiked by 201.23% to $982.0 million in 2022, then slumped by 91.75% to $81.0 million in 2023.